Why I would buy and hold CSL and these ASX healthcare shares

CSL Limited (ASX:CSL) shares are one of three in the healthcare sector that I think would be great buy and hold options…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One area of the market that I think has particularly strong long-term growth prospects is the healthcare sector.

This is due to increasing demand for healthcare products and services, thanks to the combination of population growth, better treatments, increased chronic disease burden, and ageing populations.

In light of this, I think the following three healthcare shares could be great buy and hold options:

CSL Limited (ASX: CSL)

I think this global biotech giant would be a great buy and hold investment option right now. Over the last decade the company has provided its shareholders with market-beating returns, thanks to strong earnings growth driven by the quality of its products and its high level of investment in research and development. The good news is that I believe it is well-positioned to replicate this success over the next decade, especially given its growing plasma collection network and pipeline of potentially lucrative therapies.

Pro Medicus Limited (ASX: PME)

Pro Medicus is a healthcare technology company that provides a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups worldwide. These include a suite of radiology information systems (RIS), picture archiving and communication systems (PACS), and e-health solutions, which Pro Medicus management believes constitutes one of the most comprehensive end-to-end offerings in radiology. Demand has been strong for its offering, leading to the company posting a 59.4% increase in half-year revenue to $25.3 million and a 79.9% jump in underlying half-year net profit after tax to $9.2 million earlier this year. Due to its sizeable market opportunity, I believe similarly strong growth is possible over the medium-to-long term.

RESMED/IDR UNRESTR (ASX: RMD)

ResMed is a leading developer of sleep treatment products. A recent presentation revealed that there are an estimated 1 billion people impacted by sleep apnoea worldwide. The vast majority of these people are undiagnosed and could be at risk of life-threatening conditions such as chronic daytime fatigue, heart disease, stroke, type 2 diabetes, and depression. I expect more of these undiagnosed cases to be diagnosed over the next decade, which is likely to lead to increasing demand for ResMed's industry-leading products and services.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

Here are the top five ASX 200 shares in Macquarie's model growth portfolio

These ASX 200 shares are highly rated by analysts at Macquarie.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Growth Shares

3 ASX shares to buy in 2024 and hold for the next 10 years

Analysts think these top shares are in the buy zone right now.

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Growth Shares

4 ASX growth shares I think will benefit from interest rate cuts in 2024

Not only will home loan holders rejoice, investors of these stocks could also be yelling with joy when the Reserve…

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Growth Shares

3 of the best ASX growth shares to buy now

Analysts see plenty of upside for these buy-rated shares.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Growth Shares

Here's why analysts love these buy-rated ASX 200 growth shares

There's a reason analysts are feeling bullish about these companies.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Growth Shares

Big returns could be coming for high-flying Lovisa shares

Morgans doesn't believe it is too late to snap up this hot stock.

Read more »

Smiling young parents with their daughter dream of success.
Growth Shares

Why these ASX 200 growth shares could be top buys now

Analysts are feeling bullish about these growth stocks. Let’s see what they’re saying.

Read more »

Concept image of a man in a suit with his chest on fire.
Growth Shares

Ignore the noise and buy this hot ASX growth stock

A recent pullback may have created a buying opportunity according to Bell Potter.

Read more »